Alnylam Pharmace. buy Bank of America Co.
Summary
This prediction is currently active. The BUY prediction by Bank_of_America_Co_ shows slight gains of 1.98%. This prediction currently runs until 25.06.25. The prediction end date can be changed by Bank_of_America_Co_ at any time. Bank_of_America_Co_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w |
---|---|
Alnylam Pharmace. | 1.98% |
iShares Core DAX® | 0.238% |
iShares Nasdaq 100 | -0.304% |
iShares Nikkei 225® | 2.271% |
iShares S&P 500 | -0.296% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Alnylam Pharmace. diskutieren